Literature DB >> 2984122

Stimulus interactions in release of superoxide anion (O2-) from human neutrophils. Further evidence for multiple pathways of activation.

J G Bender, D E Van Epps.   

Abstract

A wide variety of agents stimulate superoxide anion (O2-) release from human neutrophils. To determine whether the same or different cellular pathways are utilized, neutrophils were stimulated to release O2- with combinations of f-Met-Leu-Phe (FMLP) (10(-7)M), C5a (25 nM), Con A (100 micrograms/ml), arachidonic acid (100 microM), and PMA (1 microgram/ml). These concentrations produced maximal O2- production when used alone. A synergistic response was observed when Con A was used in combination with FMLP or C5a. This response was twice the expected release in cytochalasin B-treated cells and three to five times the expected release in untreated cells. Additional studies showed that synergism was dependent upon the simultaneous presence of both agents. Additive O2- responses were observed when either FMLP, Con A, or C5a was tested in combination with arachidonic acid and when FMLP and C5a were tested together. When PMA was tested with C5a, FMLP, or Con A, a nonadditive O2- response resulted, whereas mixtures of PMA and arachidonic acid resulted in a less than additive response. These contrasting results using different soluble stimuli in combination suggest that multiple pathways exist for the stimulation of neutrophil O2- release, with some stimuli being totally independent of each other (possibly activating separate pools of oxidase), while other stimuli show cooperative effects on oxidase activation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2984122     DOI: 10.1007/bf00915413

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  23 in total

1.  Activity and activation of the granulocyte superoxide-generating system.

Authors:  P E Newburger; M E Chovaniec; H J Cohen
Journal:  Blood       Date:  1980-01       Impact factor: 22.113

2.  Oxygen-dependent microbial killing by phagocytes (first of two parts).

Authors:  B M Babior
Journal:  N Engl J Med       Date:  1978-03-23       Impact factor: 91.245

3.  Stimulation of neutrophil oxidative metabolism by chemotactic peptides: influence of calcium ion concentration and cytochalasin B and comparison with stimulation by phorbol myristate acetate.

Authors:  J E Lehmeyer; R Snyderman; R B Johnston
Journal:  Blood       Date:  1979-07       Impact factor: 22.113

4.  The NADPH oxidase of human polymorphonuclear leukocytes. Evidence for regulation by multiple signals.

Authors:  L C McPhail; C C Clayton; R Snyderman
Journal:  J Biol Chem       Date:  1984-05-10       Impact factor: 5.157

5.  A potential second messenger role for unsaturated fatty acids: activation of Ca2+-dependent protein kinase.

Authors:  L C McPhail; C C Clayton; R Snyderman
Journal:  Science       Date:  1984-05-11       Impact factor: 47.728

6.  Stimulus-specific deactivation of chemotactic factor-induced cyclic AMP response and superoxide generation by human neutrophils.

Authors:  L Simchowitz; J P Atkinson; I Spilberg
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

7.  Respiratory burst enzyme in human neutrophils. Evidence for multiple mechanisms of activation.

Authors:  L C McPhail; P M Henson; R B Johnston
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

8.  Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

9.  cis-Polyunsaturated fatty acids induce high levels of superoxide production by human neutrophils.

Authors:  J A Badwey; J T Curnutte; M L Karnovsky
Journal:  J Biol Chem       Date:  1981-12-25       Impact factor: 5.157

10.  Chemotactic factor enhancement of superoxide release from fluoride and phorbol myristate acetate stimulated neutrophils.

Authors:  D English; J S Roloff; J N Lukens
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

View more
  7 in total

1.  Effects of fibrinogen derivatives upon the inflammatory response. Studies with human fibrinopeptide B.

Authors:  R M Senior; W F Skogen; G L Griffin; G D Wilner
Journal:  J Clin Invest       Date:  1986-03       Impact factor: 14.808

2.  Silibinin (Legalon-70) enhances the motility of human neutrophils immobilized by formyl-tripeptide, calcium ionophore, lymphokine and by normal human serum.

Authors:  L Kalmár; J Kádár; A Somogyi; P Gergely; G Csomós; J Fehér
Journal:  Agents Actions       Date:  1990-03

3.  Alterations in neutrophil superoxide production following piroxicam therapy in patients with rheumatoid arthritis.

Authors:  D E Van Epps; S Greiwe; J Potter; J Goodwin
Journal:  Inflammation       Date:  1987-03       Impact factor: 4.092

4.  Oxygen radical production by neutrophils from patients with bacterial infection and rheumatoid arthritis. Measurement of hydrogen peroxide may most accurately represent enhancement of oxygen radical production during infection.

Authors:  Y Ozaki; T Ohashi; Y Niwa
Journal:  Inflammation       Date:  1986-06       Impact factor: 4.092

5.  A Potential Role for Acrolein in Neutrophil-Mediated Chronic Inflammation.

Authors:  Brett D Noerager; Xin Xu; Virginia A Davis; Caleb W Jones; Svetlana Okafor; Alicia Whitehead; J Edwin Blalock; Patricia L Jackson
Journal:  Inflammation       Date:  2015-12       Impact factor: 4.092

6.  Trimellitic anhydride-induced allergic response in the lung: role of the complement system in cellular changes.

Authors:  D G Fraser; J F Regal; M L Arndt
Journal:  J Pharmacol Exp Ther       Date:  1995-05       Impact factor: 4.030

Review 7.  Activation of the respiratory burst oxidase in neutrophils: on the role of membrane-derived second messengers, Ca++, and protein kinase C.

Authors:  J D Lambeth
Journal:  J Bioenerg Biomembr       Date:  1988-12       Impact factor: 2.945

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.